Detailed analysis of the pharmacological mechanism of pimetibib

Pimitespib is a highly selective HSP90 inhibitor that mainly acts on Heat Shock Protein 90 (HSP90), a key molecular chaperone in cancer cells. HSP90 is widely present in mammalian cells and is an important regulator of the survival, proliferation and drug resistance of various cancer cells. By inhibiting the activity of HSP90, pimetibib blocks its function of stabilizing and activating a variety of oncogenic proteins, leading to the collapse of multiple signaling pathways in tumor cells, ultimately inducing cell apoptosis or inhibiting proliferation, especially in cancers where tumor driving factors are highly dependent on HSP90.

From a pharmacological mechanism perspective, HSP90 is involved in the folding and conformational stabilization of key proteins in various oncogenic pathways such as EGFR, HER2, AKT, BRAF, c-MET, ALK, VEGFR, etc. In tumor cells, these proteins are often overexpressed or mutated, making them more dependent on HSP90 for stabilization. Therefore, inhibition by pimetibib not only leads to the degradation of these key proteins but also interrupts multiple oncogenic pathways simultaneously. Compared with traditional single-target TKIs (tyrosine kinase inhibitors), pimetibi has greater therapeutic potential in complex and heterogeneous cancers, and is especially suitable for patients with solid tumors that have developed drug resistance after multiple lines of treatment.

Different from earlier HSP90 inhibitorsPimetibi’s chemical structure design optimizes oral bioavailability and tissue penetration, significantly reducing liver toxicity and retinal toxicity that were common with previous HSP90 inhibitors. This structural optimization also enables it to stably inhibit HSP90 ATPase activity in vivo while maintaining low systemic toxicity. In various tumor models such as gastrointestinal stromal tumor (GIST), liver cancer, and biliary tract cancer, pimetibi has demonstrated broad-spectrum anti-tumor activity, especially in tumor subtypes that are resistant to traditional TKIs. It provides a new treatment idea through the indirect degradation of dependent proteins such as KIT and PDGFRA.

Reference materials:https://en.wikipedia.org/wiki/Pimitespib